Old Articles: <Older 7941-7950 Newer> |
|
IndustryWeek October 19, 2011 |
FDA: A Future Innovation Partner? Could the Food and Drug Administration reform itself to help manufacturers create new medical technologies? |
The Motley Fool October 19, 2011 Brian Orelli |
This High-Tech Company Still Has the Touch Intuitive Surgical beats analysts' expectations. Again. |
The Motley Fool October 19, 2011 Selena Maranjian |
Make Money in Strong Pharma Stocks the Easy Way If you expect the pharmaceutical industry to thrive as our global population grows and ages, the iShares Dow Jones US Pharmaceuticals ETF could save you a lot of trouble. |
The Motley Fool October 17, 2011 |
Laboratory Corp. of America Holdings Earnings Preview Laboratory Corp. of America Holdings will unveil its latest earnings on Thursday, October 20, and analysts predict a rise of 10% in revenue. |
The Motley Fool October 18, 2011 Brian Orelli |
How Not to Gain 75% of Your Company's Value Overnight A 75% increase in price certainly seems possible, but not until investors are convinced that Sequenom can execute on its sales plan the way it has on its clinical plan. |
The Motley Fool October 18, 2011 Evan Niu |
Halozyme Therapeutics Shares Surged: What You Need to Know Shares of Halozyme Therapeutics are surging by as much as 22.5% today on news that, together with partner Roche Holding, the company has reported positive results from a trial study regarding one of its drugs. |
The Motley Fool October 18, 2011 Alexander Crawford |
Biotech M&A: Analyst Gives 5 Potential Targets in Biomedical Devices Are these biomedical companies likely candidates for a takeover? |
The Motley Fool October 14, 2011 Sean Williams |
7 FDA Decisions You Can't Afford to Ignore in Q4 These stocks are bound to move as the FDA weighs in on their prospective drugs in Q4: Bristol-Myers... BioSante... Teva... Regeneron... Transcept... Incyte... Antares Pharma... |
The Motley Fool October 13, 2011 Sean Williams |
How to Turn Onyx Into Gold A settlement with Bayer turns Onyx into an instant buyout candidate. |
The Motley Fool October 12, 2011 Alex Dumortier |
Buy WellPoint's Share Buyback Share buybacks are a contrarian indicator, but not WellPoint's. |
<Older 7941-7950 Newer> Return to current articles. |